Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-14
2010-11-16
Morris, Patricia L (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07834187
ABSTRACT:
The present invention relates to a crystalline variable hydrate of (S)-(3-pyridinecarboxamide,6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy]) -hemi-succinate, a pharmaceutical formulation containing said salt and to methods for treating obesity and/or Type 2 diabetes using said salt.
REFERENCES:
patent: 6627646 (2003-09-01), Bakale et al.
patent: 7041684 (2006-05-01), Rito et al.
patent: 0 827 746 (1998-03-01), None
Vippagunta et al., “Crystalline solids”, Advanced Drug Delivery Reviews 48 (2001) 3-26.
Ulicky et al., Comprehensive Dictionary of Physical Chemistry, NY Ellis Horwood PTR Prentice Hall, 1992, p. 21.
Siilverman, The Organic Chemistry of Drug Design and Drug Action, NY: Academic Press, Inc. 1993, 72-76.
Rowland and Tozer. “Clinical Pharmacokinetics, etc.,” 1995, p. 123.
Jain et al., “Polymorphism in Pharmacy”, Indian Drugs, 1986, 23(6) 315-329.
Chemical & Engineering News, Feb. 2003, 32-35.
US Pharmacopia #23, Nationa Formulary #18, 1995, 1843-1844.
Caira, “Crystalline Polymorphism, etc.,” Topics in Current Chemistry, 198, Berline Heidelberg: Springer Vertag, 1998, pp. 164-208.
Wilbraham et al. “Organic and biochemistry . . . ” p. 250-251 (1985).
Garattini “Active drug metabolites . . . ” Clin. Pharmacokinetics v.10, p. 216-227 (1985).
Muzaffar et al., “Polymorphism, etc.,” Journal of Pharmacy (Lahore) 1979, 1(1), 59-66.
Guillory (in Brittain ed.) “Polymorphism, etc.,” NY: Marcel Dekker, Inc., 1999, 1-2, 125-146, 149-181, 183-226.
CMU Pharmaceutical polymorphism, intenet p. 1-3 (2002) (printout Apr. 3, 2008).
Singhal et al., “Drug polymorphism, etc.,”Advanced drug delivery reviews 56, 335-347 (2004)..
Czeskis, B., et al., “Synthesis of β3 adrenergic receptor agonist LY377604 and its metabolite 4-hydroxycarbazole, labeled with carbon-14 and deuterium,”J Label Compd Radiopharm, 48: 407-419 (2005).
Miller, JW, et al., “Stimulation of Energy Expenditure by LY377604, a beta3-Adrenergic Receptor Agonist with beta 1/2-Antagonist Properties in Healthy Male Subjects,”Obesity Research, 7(Supp. 1), p. PF17. The North American Association for the Study of Obesity (1999).
Demeter John C.
Eli Lilly and Company
Morris Patricia L
Voy Gilbert T.
LandOfFree
Crystalline variable hydrate of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline variable hydrate of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline variable hydrate of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4251697